Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 4, pp 171–175 | Cite as

Consider lithium for the treatment of bipolar disorder in paediatric patients

  • Adis Medical WritersEmail author
Disease Management
  • 6 Downloads

Abstract

Bipolar disorder can occur in anyone, including children. Atypical antipsychotics are generally considered first-line treatment for paediatric bipolar disorder, and lithium is often chosen as a treatment of last resort perhaps because of its narrow therapeutic window and potential adverse effects. However, lithium reduces the risk of suicidality, and new dosing paradigms have reduced potential adverse effects and improved tolerability. Therefore, treatment with lithium may be worth the burdens of careful monitoring and adverse effect management.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Pediatric Drugs 2018;20(4):303–14 [3] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    National Institute of Mental Health. Bipolar disorder in children and teens. 2015. https://www.nimh.nih.gov/health/publications/bipolar-disorder-in-children-and-teens/index.shtml. Accessed 2018.
  2. 2.
    Parens E, Johnston J. Controversies concerning the diagnosis and treatment of bipolar disorder in children. Child Adolesc Psychiatry Ment Health. 2010;4:9.CrossRefGoogle Scholar
  3. 3.
    Grant B, Salpekar JA. Using lithium in children and adolescents with bipolar disorder: efficacy, tolerability, and practical considerations. Pediatr Drugs. 2018;20(4):303–14.CrossRefGoogle Scholar
  4. 4.
    Abilify® (aripiprazole tablets, oral solution and injection) and Abilify® Discmelt® (aripiprazole orally disintegrating tablets): US prescribing information. Rockville: Otsuka America Pharmaceutical Inc.; 2018.Google Scholar
  5. 5.
    Saphris® (asenapine) sublingual tablets: US prescribing information. Irvine: Allergan USA Inc.; 2017.Google Scholar
  6. 6.
    Latuda® (lurasidone hydrochloride) tablets: US prescribing information. Marlborough: Sunovion Pharmaceuticals Inc.; 2018.Google Scholar
  7. 7.
    Zyprexa® (olanzapine tablet and intramuscular injection) and Zyprexa® Zydis® (olanzapine orally disintegrating tablet): US prescribing information. Indianapolis: Lilly USA, LLC; 2018.Google Scholar
  8. 8.
    Symbyax® (olanzapine and fluoxetine) capsules: US prescribing information. Indianapolis: Lilly USA, LLC; 2018.Google Scholar
  9. 9.
    Seroquel® (quetiapine fumarate) tablets: US prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  10. 10.
    Seroquel XR® (quetiapine fumarate) extended-release tablets: US prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  11. 11.
    Risperdal® (risperidone tablets and oral solution) and Risperdal® M-Tab® (risperidone orally disintegrating tablets): US prescribing information. Titusville: Janssen Pharmaceuticals, Inc.; 2018.Google Scholar
  12. 12.
    Lithium (oral solution) and lithium carbonate (tablets and capsules): US prescribing information. Eatontown: West-Ward Pharmaceuticals Corp.; 2018.Google Scholar
  13. 13.
    Lithobid® (lithium carbonate) extended-release tablets: US prescribing information. Baudette: ANI Pharmaceuticals; 2018.Google Scholar
  14. 14.
    National Institute of Mental Health. Bipolar disorder: overview. 2016. https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml. Accessed 2018.
  15. 15.
    Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.CrossRefGoogle Scholar
  16. 16.
    Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics. 2015;136(5):885–94.CrossRefGoogle Scholar
  17. 17.
    Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69(5):515–28.CrossRefGoogle Scholar
  18. 18.
    Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):289–97.CrossRefGoogle Scholar
  19. 19.
    Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(5):409–17.CrossRefGoogle Scholar
  20. 20.
    Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37(2):171–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations